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This year’s annual report focuses upon
neuroblastoma, a childhood cancer that
primarily occurs in the youngest of our
patients, those less than 5 years of age.
Over the years, research has shown that
though most neuroblastoma tumors have
relatively similar appearances under the
microscope, there are in fact two unique
forms of this cancer with widely different
chances of cure. As you will read in this
report, this has allowed us to identify these
groups, and to reduce therapy to those who
can be cured with less, and to increase
therapy to those who need more for an
improved cure.
This rapidly improving understanding
of this childhood cancer is a result of the
collaborative nature of childhood cancer
specialists. In this ubiquitous clinical
research culture, specific therapies are
rapidly evaluated and when successful
incorporated into the standard of care. The
rapidity of this improvement is in direct
correlation with the percentage of children
participating in clinical trials. In the United
States, virtually all children with cancer
are treated at institutions that participate
in the National Cancer Institute-sponsored
Children’s Oncology Group (COG). Compare
this to the 1-2 percent of adults treated
on clinical trials. Studies have repeatedly
shown that children receiving their care at
one of the COG centers as opposed to other
locations have significantly better outcomes,
and those treated on clinical trials have an
even better chance for cure. Clinical trials
allow us to provide the best known care or a
therapy that may be even better which may
become tomorrow’s best known care. One
can easily see why the cure rates in children
have improved more rapidly than in adults.
The timing of this report and its subject
offers us the opportunity to highlight the
50th anniversary of the work of the National
Cancer Institute’s Cooperative Clinical
Trial Group model. For children, this is
represented by COG, merged in 1999 from
the prior Pediatric Oncology Group (POG) and

Children’s Cancer Study Group (CCSG). The
COG is a multi-institutional organization that
includes over 240 institutions that provide
>99 percent of the care for childhood
cancer patients in the United States,
Canada, Australia, New Zealand, and parts
of Europe. Virtually every childhood cancer
specialist in the country is a participant in
this enormous clinical trial organization.
It is the largest such cooperative group
in the world and dwarfs similar groups in
other parts of the world who have modeled
their organizations after the COG and its
predecessors. It incorporates all the major
university and cancer specialty hospitals
in these countries and as a result provides
infinitely more resources to the individual
patient than any single center could alone.
Research scientists and clinicians from these
240+ centers work jointly and collaboratively
to advance the field of childhood cancer
therapy and to improve the rates of cure
in our patients. This organization brings
together the laboratory research of the basic
scientists, and the massive numbers of
patients cared for by the clinicians, allowing
the clinical and translational research
investigators to offer the most advanced
treatment for childhood cancer victims
through their local or regional childhood
cancer specialists wherever they live in this
country. As the COG celebrates its 50th
anniversary of work towards eliminating this
disease as the major cause of non-traumatic
death in children, one can truly say that the
care one receives in Los Angeles, Houston,
New York, Rochester, or Kansas City, is the
same in all centers. With this availability,
parents and their child may remain close to

home and within their network of support,
which is unavailable to them when far from
home.
	Children’s Mercy is the region’s largest
as well as one of the larger childhood
cancer centers in the country, and as result
of its multi-specialty and multi-disciplinary
coordinated care system, outcomes match
or exceed those seen nationally. Several
national and international clinical trials are
led by Children’s Mercy physician scientists.
As an academic and clinical center, it
employs a large number of people, including
research data managers, pharmacists, and
nurses, whose sole jobs are the operation
of these cutting edge clinical trials at our
hospital. I invite the reader to visit our Web
site, www.childrensmercy.org, where this is
further illustrated and to visit the Web sites
of the National Cancer Institute,
www.cancer.gov, and the Children’s Oncology
Group, www.curesearch.org, to learn more
about these cooperative efforts and the
latest laboratory and clinical trials available
to children with cancer. These trials, the
majority available here at Children’s Mercy,
offer our children with cancer the latest
advances of therapy while simultaneously
providing the knowledge necessary to
improve the care for children of the future.
Sincerely,

Alan Gamis, MD, MPH
Director of Oncology
Chair, CMH Cancer Center Committee

Dear Friends,
It is with pleasure that I share with you the 2005 Cancer Care Annual Report from
Children’s Mercy Hospitals and Clinics. This year’s report includes a special focus on our work
with neuroblastoma, but also will provide you with an overview of the many different clinical
and psychosocial programs we provide for children with cancer and their families.
	As a parent, I can’t imagine how traumatic it must be to hear a physician tell you that
your child has cancer. The staff of our Division of Hematology/Oncology is well aware of how
that news can impact a family, and works closely with all members of the family from the
moment the diagnosis is received, through treatment and follow-up and into remission. And,
thanks to the cutting-edge research in which our staff participates and our sharing of research
with other pediatric programs throughout the country, we are able to continue improving the
outcomes and survival rates for children with all different types of cancer.
I hope you will take a few moments to review this annual report to learn more about our
latest work fighting neuroblastoma and other cancers which affect our children and teens.
All of us at Children’s Mercy are extremely proud of the care provided by the Division of
Hematology/Oncology and the strength and hope which our patients and their families share
with us.
Sincerely,

Randall L. O’Donnell, PhD
President and Chief Executive Officer



patrick
After a month of taking antibiotics
prescribed by his doctor, Patrick
became severely ill while away on family
vacation. His parents rushed him home
and called his doctor, who referred
them to Children’s Mercy Hospital.
Patrick’s parents brought him into the
hospital on July 29, 2003 and that night
he was diagnosed with neuroblastoma.
The next day, Patrick had a biopsy to
remove part of a tumor in his abdomen.



As a typical 6-year-old boy, Patrick
loved playing t-ball and was always
causing mischief. Halfway through
t-ball season, however, Patrick began
complaining about feeling sick and
didn’t want to play. At first his parents
thought he had just lost interest in the
game, but they soon found out that
something more was wrong.

Over the course of the next couple
months Patrick underwent four rounds
of chemotherapy. Then, in October
of 2004, he had a major operation
to remove the remainder of the large
tumor that had wrapped itself around
his abdomen. After more chemotherapy
and radiation, Patrick had a stem cell
transplant in March of 2004. He then
had another operation in June of 2004
to remove a tumor in his chest

routine visits to Children’s Mercy every
three to four months, but spends the
rest of his time at school or playing
sports.

After a long fight, Patrick is now a
healthy 9-year-old boy. He still makes

Keep your eye on the ball
Patrick!

division of
		 hematology/oncology
	Excellent comprehensive care
for children with cancer and other
blood disorders is the mission
of members of the Division of
Hematology/Oncology at Children’s
Mercy Hospitals and Clinics.
Children and families served by the
Division receive care both in the
Hematology/Oncology Clinic and
on 4 Henson, the inpatient floor.
Each area is specially equipped to
care for patients during each phase
of their treatment. Additionally,
caregivers are given specialized
training that continues throughout
their Hematology/Oncology career.
Over 40 nurses within the Division
currently hold Certified Pediatric
Oncology Nurse certification.
The Division of Hematology/
Oncology is led by Division
Chief, Gerald Woods, MD. Dr.
Woods also leads the Section
of Hematology and Alan
Gamis, MD, MPH is the Chief
of the Section of Oncology.
Sue Stamm, RN, CPNP is the
Manager of the Division. The
following is an overview of the
Division and its services.



The Section of Oncology
Section Chief - Alan Gamis, MD
n

Oncology Service-Director-Alan
Gamis, MD, MPH: Six physicians
provide care to patients diagnosed with
oncology disorders. Patients are treated
according to state-of-the-art protocols
endorsed by leaders in children’s cancer
treatment.

n

Bone Marrow Transplant ServiceDirector-Charles Peters, MD: Two
dedicated transplant physicians provide
hematopoietic stem cell rescue to
patients receiving myelo-suppressive
or ablative therapy which requires
stem cell rescue. Stem cell rescue
is accomplished by utilizing umbilical
stem cells, matched-related donor cells,
and matched-unrelated donor cells.
Children’s Mercy Hospital participates
in the National Marrow Donor Program
which facilitates unrelated donor
searches for patients who have such a
need.

The Section of Hematology
Section Chief - Gerald Woods, MD
n

Sickle Cell Disease ServiceService Director-Gerald Woods,
MD: The Sickle Cell service offers
specialized care for the unique
diagnostic and treatment needs of
children and adolescents diagnosed with
sickle cell disease. The patients and
families are cared for during episodes
of acute pain and receive on-going
management for life limiting chronic
pain, and other long term issues related
to their disease.

n

Regional Hemophilia Center-Center
Director-Brian Wicklund, MD: The
Center supports seven sites in a fivestate region to provide comprehensive
treatment for both adult and pediatric
patients with bleeding disorders.
Additionally, this service supports the
diagnosis and treatment of children with
coagulation and/or thrombosis disorders.

Pediatric Hematology/Oncology Fellowship Program



The fellowship program at Children’s Mercy Hospital trains the future pediatric
hematology/oncology specialists. This program requires intense clinical and research training
for a minimum of three years. Each fellow at Children’s Mercy Hospital enters the fellowship
program as a fully trained pediatrician. The first 18 months are dedicated primarily to clinical
care and becoming familiar with procedures and standards of practice. The last half of the
fellowship is focused upon clinical and laboratory research. The Division of Hematology/
Oncology at Children’s Mercy Hospital supports three fellowship positions.

Children’s Mercy
Cancer Care Committee
The Children’s Mercy Hospital Cancer
Care Committee is a standing medical
staff committee that provides oversight of
the oncology services. The committee is
chaired by the section chief for the Section
of Oncology and has both physician and
non-physician representation (see member
listing). At quarterly meetings the committee
reviews patient acuity, program services
and quality initiatives. They also determine
quality improvement needs and opportunities
related to pediatric cancer prevention,
diagnosis, treatment, and outreach. The
committee functions in accordance with the
American College of Surgeons’ accreditation
standards.

Psychosocial Services
n

Parent-to-Parent Program: designed
to connect parents who have been
through the cancer experience with
parents of a newly diagnosed child
with cancer. In addition, this program
offers support groups on a weekly basis
facilitated by parent volunteers under
the oversight of a social worker.

n

Social Work and Community
Services: there are five full-time social
workers dedicated to the Division of
Hematology/Oncology. The primary
focus of this team is to assist the patient
and the family in understanding the
impact the diagnosis of cancer will have
on their family dynamics and life style.

n

Bereavement Support Group/
Program: this program is offered to
parents who have experienced the loss
of a child. The program includes staff
contacts to parents/family members
during significant events such as
birthdays, anniversary date for the death
of the child, an annual memorial service,
and the composition of a memory book.

n

Child Psychologist: a full-time
psychologist provides support to the
patient, parents, and siblings of those
diagnosed with childhood cancer.

n

Chaplaincy: the hospital offers
chaplaincy service 24 hours each day.
Within the Division, a full-time chaplain
supports the spiritual needs of the
patient and their families.

n

Child Life Therapist/Music
Therapist: two full-time Child Life
therapists, one full-time Child Life
assistant and one part-time music
therapist work with patients, parents,
and siblings to aid in the adjustment
and ongoing support associated with
diagnosis and treatment of childhood
cancer.

n

Cancer Outreach/School Re-entry
Services Participants: a team of
Division members including nursing
and social work work to build strong
connections among the hospital,
parents/child, and each child’s school.
School staff is provided with important
information and are encouraged to ask
questions. This effort allows for a better
level of comfort/understanding while
interfacing with the child and family.
Additionally, school mates are given
accurate information and are able to ask
questions to relieve anxieties.



Cancer Care Conferences
The Children’s Mercy Cancer Center
conferences provide opportunities for a
multidisciplinary discussion regarding newly
diagnosed patients, recurrent/relapsed
patients, and unusual pediatric cancer
cases. Conference participants review
patient history, physical findings at diagnosis,
laboratory values, radiology exams, surgical
interventions, and pathological findings. This
diagnostic review is followed by a thorough
review of the potential treatment options,
current therapy available, response to
therapy and prognosis. Medical specialists
from oncology, surgery, pathology, radiology,
radiation oncology, neurosurgery, orthopedic
surgery, endocrine, psychology, and dentistry
are represented. In addition, non-physician
team members are encouraged to attend.
Conferences are conducted in accordance
with the American College of Surgeons’
accreditation standards.
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Case Management

Outreach and Prevention

	Each physician within the Hematology/
Oncology Division works in close
collaboration with an advanced practice
nurse, physician assistant or nurse in
expanded role. With the assistance of an
assigned social worker, these individuals
coordinate every aspect of the patient’s
care throughout treatment and during posttreatment follow-up.

In addition to providing support for
current patients, members of the Division
also provide preventive education/outreach
on issues such as smoking cessation and
sun exposure. These programs are tailored
to the appropriate age group being spoken
to.

Nutrition/Pharmacy Services

Opportunities to participate in research
are plentiful within the Division. Research
studies in all areas are always open and
recruiting new participants. All studies are
reviewed by the Children’s Mercy Institutional
Review Board to ensure that the studies
are safe, equitable and hold some form of
benefit. Children’s Oncology Group (COG)
studies comprise the majority of studies
available to oncology patients. These
studies are created by a cooperative group of
over 175 institutions. Member researchers
continue to develop research trials that bring
improved care and outcome to pediatric
patients. In addition to COG studies, the
Division participates in studies sponsored by
the National Institutes of Health, Centers for
Disease Control, pharmaceutical companies,
and various other research leaders. A team
of research coordinators and data managers
facilitate patient enrollment and follow-up
during study participation.

n

Nutrition: two full-time and one parttime registered dietician support the
nutrition needs of the patient/family. In
addition, there is a nutrition tech that
adds support to the team.

n

Pharmacy: two full-time pharmacists
and one full time technician support
the operations of a satellite pharmacy
Monday -Friday, 7:00 a.m. to 7:30 p.m.
This satellite supports the inpatient
and outpatient areas in preparing and
dispensing chemotherapy. In addition,
one full-time pharmacist provides clinical
consultation to the oncology service and
one full-time pharmacist provides clinical
support to the Bone Marrow Transplant
Service.

Research

petra
After finding what looked like a shadow
on her sonogram, doctors gave 37
week pregnant Candice an hour to go
home and pack a bag and return to the
hospital to deliver her baby. On July 8,
2005 Petra was born through C-section
and diagnosed with neuroblastoma.
The next morning a transport team
arrived to bring Petra to Children’s
Mercy.
“I held her for hours before they came
to get her,” says Candice. “The team
patiently waited until I could bear to
give her up, then they took her and
strapped her into a little five point
harness. I felt like the Calvary had
come and she was going to be fine.”

Petra spent nearly a month in the NICU
at Children’s Mercy. A week after her
arrival Petra had surgery to remove
her tumor. She was then sent home in
hopes that her immune system would
take care of the remainder of the
cancer.
However, a couple weeks before
Christmas, Petra’s pediatrician sent
her back to Children’s Mercy after
her parents noticed bruises under
her eyes and small bumps on her
forehead. Tests showed that the cancer
had moved to her skull, and Petra
was instantly moved into a high risk
category and started chemotherapy in
February to combat the cancer.
After eight rounds of chemotherapy,
tests showed that the cancer was
gone from Petra’s skull. However, an
antibody test showed that there might
be fragments left in her bone marrow,
and there was still some cancer in her
liver that was receding on its own.

Today Petra is a healthy 2 year old girl,
and her body has continued fighting
the cancer left in her liver. Petra has
developed right on schedule with other
kids her age, and is even ahead of other
kids in some categories.
Young Petra has lived up to her name,
translated from Greek to mean rock,
and is definitely a force to be reckoned
with.

Stay strong Petra!
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cancer care
committee
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Medical Staff Members
Andrews, Walter, MD				
Surgery
Burleson, Amy, DDS				
Dentistry
Cooley, Linda, MD				Cytogenetics
Covitz-Hardy, Lynne, PhD				
Developmental Medicine
Dalal, Jignesh, MD				
Hematology/Oncology
						
Stem Cell Transplant
Emami, Abbas, MD
Hematology/Oncology
Gamis, Alan, MD, MPH Chairman
Hematology/Oncology
Gyves-Ray, Katherine, MD			Radiology
Hetherington, Maxine, MD Assistant Chairman
Hematology/Oncology
Holcomb, George W., MD				
Surgery
Hornig, Gregory, MD				Neurosurgery
Huseman, Carolyn, MD				Endocrinology
Lewing, Karen, MD				
Hematology/Oncology
Manalang, Michelle, MD				
Hematology/Oncology
Massey, Vickie, MD				Radiation Oncology
Modrcin, Ann, MD				Rehabilitation Medicine
Morello, Frank, MD
	Radiology
Nicklaus, Pam, MD				
Otorhinolaryngology		
Peters, Charlie, MD				
Hematology/Oncology
						
Stem Cell Transplant
Sharma, Mukta, MD				
Hematology/Oncology Fellow
Shore, Richard, MD				
Hematology/Oncology		
Snyder, Charles, MD				
Surgery-ACOS Liaison
Woods, Gerald, MD				
Hematology/Oncology
Zwick, David, MD				
Pathology
Non-Physician Members
Baer, Phyllis, RN					
Hematology/Oncology
Bartholomew, Joy, RN, FNP, CPON		
Hematology/Oncology
Brown, Pat, MS, FT
			
Hematology/Oncology
Burns, Susan, RN, CPON				
Hematology/Oncology
Corse, Cindy, CTR				Cancer Registry
Devorin, Barb, RN, CPNP				Neurosurgery
Fournier, Julie, RN, CPON				
Hematology/Oncology
Green, Nancy, Sr. CNS				Nutrition
Haynes, Cindy, MDIV, BCC			Chaplaincy Services
Hamlin, Julie, APRN, BC				
Hematology/Oncology
Hutto, CJ, RN, CPON				
Senior Director Allied Health
Jones, Ronald, PA-C				
Hematology/Oncology
Klockau, Chris, RPh, BCOP			
Pharmacy
Laurence, Kris, CCRP				
Hematology/Oncology
Marcus, Bette, RN, CPON			
Hematology/Oncology
Mick, Kathy, RN, CPON				Education
Ryan, Robin, CCRP				
Hematology/Oncology
Seal, Annie, C.L.S.				Child Life
Smith, Courtney, Pharm D			
BMT/Pharmacy
Stamm, Susan, RN, MSN, PNP			
Hematology/Oncology
Stegenga, Kristin, RN, PCNS, CPON
Hematology/Oncology
Thompson, Mandy, Nurse Clinician
Hematology/Oncology
VanStone, Jill, RN MSN, PCNS			
Hematology/Oncology
Walter, Christy, CCRP, LPN			
Hematology/Oncology

richard
After arriving at
Children’s Mercy, Richard
was diagnosed with
neuroblastoma on February
21, 2006. He had an
operation two days later to
remove his adrenal gland
and the majority of the tumor
in his liver. Richard then
started his first of eight
rounds of chemotherapy.
As a 4-month-old baby boy, Richard was
described as a healthy kid who always
had a smile on his face. While his smile
never faded, Richard’s health became
an issue when his mother noticed his
stomach steadily enlarging.
“I thought we were just feeding him
too much so I asked his doctor about it
when I took him to get his shots,” says
Amy, Richard’s mother. “The doctor
sent us straight to Children’s Mercy.”

During Richard’s second round of
chemotherapy he had to be placed
on a ventilator because his swollen
liver had caused his lungs to become
compressed. Eventually, the swelling
started to go down and Richard was
taken off of the ventilator. Richard
continued with his chemotherapy
and didn’t encounter any other major
problems. He finished chemotherapy
in August of 2006 and was soon sent
home.

Today Richard is an energetic 16month-old who still sports the
trademark smile that never left his
face. He still has a feeding tube, but
eats most of his food through his mouth
and is even getting close to walking!

Keep smiling Richard!
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cancer registry
PURPOSE

PROCEDURES

Historical Mandate: The National Cancer
Act in 1971 signed by President Richard
Nixon, made the “conquest of cancer a
national crusade” by mobilizing the country’s
resources to fight cancer. In October of
1992, congress enacted Public Law 102515 which established the National Program
of Cancer Registries. This law authorized the
Centers for Disease Control and Prevention
(CDC) to enhance centralized cancer registry
operations in all states.

Quality and Supervision: The Cancer
Registry operates under the guidance of the
Cancer Care Committee. Quality of data
is monitored by the committee with timely
reports and audit reviews.

The Children’s Mercy Hospital (CMH)
submissions: Confidential, protected
data is reported to the Missouri State
Central Registry. CMH also maintains
accreditation approval from the American
College of Surgeons Commission on Cancer;
which requires data be submitted to the
National Cancer Data Base. With this data,
public health professionals are enabled to
understand and address the cancer burden
more effectively.
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CMH Registry Goal: The ultimate purpose
of the cancer registry data is to establish
cancer statistics. Reporting includes
incidence, mortality and pattern identifying
features, in order to assist research for
fighting cancer.

Operations: The Registrar captures a
complete summary of the history of illness,
diagnosis, treatment, and disease status
for every cancer patient that is diagnosed
or treated with a malignancy at CMH
and clinics. Certain benign / borderline
conditions are also collected as approved
by the Cancer Care Committee. The Cancer
Registry also conducts yearly follow-up
contacts of all patients in the registry until
age 27.

2005 REGISTRY STATISTICS
Numbers: During 2005, 152 new cases
were added to the registry. During the time
period from January 1, 1990 until December
31, 2005 data has been collected on 1,536
patients.
Age and Sex at Diagnosis: There
were 16 patients less than 1 year of age
diagnosed in 2005. 75 patients were in
the 1-10 age group and 61 patients were
greater than 10 years of age. During 2005
there were 83 males and 69 females
diagnosed.

Histological Implications: Leukemia was
the leading diagnosis in 2005 representing
28 percent of the annual caseload. This
was the first year since 2002 that the
leukemia diagnosis outnumbered the
tumors of the central nervous system.
The five most frequently occurring
diagnoses for 2005 were; leukemia, CNS
tumors, lymphoma, neuroblastoma and
osteosarcoma. (see figure 1 and 3)
Analytic Patients: During 2005 there were
132 analytic patients. The analytic patients
are those diagnosed here or elsewhere,
but received all or part of the first course of
treatment at CMH. The analytic patients are
those eligible for inclusion in the registry’s
statistical reports of treatment efficacy and
survival.
Mortality: There were 22 cancer-related
deaths reported during 2005, 6 of these
patients were also diagnosed in 2005.
Tumors of the central nervous system
represented 32 percent of these mortalities.
(see figure 2)

CHILDREN’S MERCY HOSPITAL
CANCER REGISTRY
2005 FREQUENCY OF DIAGNOSIS
FIGURE 1

2005 MORTALITY DATA
FIGURE 2

Central Nervous System
	Astrocytoma
Glioma
Medulloblastoma
	Ependymoma
Glioblastoma Multiforme
Germinoma
Mixed Germ Cell of CNS
Oligodendroglioma
	Choroid Plexus Carcinoma
Benign/Borderline Tumors

37 (24%)
7
7		
3
1
1
1
1
1
1		
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Leukemia
	ALL
	AML
Juvenile myelomonocytic
	Acute promyelocytic
	Chronic myelogenous

42
33
6
1
1
1

Lymphoma
	Non-Hodgkins
Hodgkins

15 (10%)
6		
9

(28%)

Neuroblastoma

7

(5%)

Osteosarcoma

7

(5%)

Wilms Tumor

5

(3%)

Rhabdomyosarcoma

4

(3%)

Ewings Sarcoma (EFT)

2

(1%)

Other
	Congenital Fibrosarcoma
	Embryonal Carcinoma
Lymphoproliferative Dis.
Malignant Rhabdoid Tumor
Malignant Teratoma
Melanoma
Mixed Germ Cell
Myelodysplastic syndrome
	Retinoblastoma
Squamous Cell Carcinoma
Thyroid Carcinoma
Yolk Sac Tumor
Misc. Reportable conditions

7

Leukemia		

3

Wilms Tumor		

2

Osteosarcoma 		

2

Germ Cell		

1

Hepatoblastoma		

1

Hodgkin Disease		

1

Lymphoproliferative Disorder		

1

Malignant Rhabdoid of Kidney		

1

Neuroblastoma		

1

Rhabdomyosarcoma		

1

Undifferentiated Sarcoma		

1

A five-year comparison of most frequently occurring diagnoses
at children’s Mercy hospital
FIGURE 3

33 (21%)
1
1
1
1
1		
1
2
2
1
1
3
2
16

*The Cancer Care Committee has approved the
following conditions to be included in the registry.
These conditions are included in the registry due
to location of tumor or because of its propensity
to recur.
Mesoblastic nephroma
Teratomas, regardless of locations
Theca cell-granulose cell tumors
Lymphoproliferative Disease
Langerhan’s Cell Histiocytosis
Hemangioendothelioma
		
		

Central Nervous System		
Atypical teratoid/rhabdoid
1
Choroid Plexus Carcinoma
1
Ependymoma
3
Glioblastoma Multiforme
1
Glioma
1

15

Total Diagnoses

santana
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Eight-year-old Santana is a vibrant
young girl who enjoys participating
in Girl Scouts and loves all animals,
especially the miniature horses
that her family raises. Today no one
would expect that Santana had a long
fight with cancer, but the doctors at
Children’s Mercy know that this little
girl is a fighter!

Santana was admitted into Children’s

When Santana was 18 months old
her mother took her to the doctor
because she had flu like symptoms, her
stomach was slightly enlarged, and her
lymph nodes were hard. A CAT scan
found neuroblastoma, and the doctor
immediately sent Santana to Children’s
Mercy.

Santana then received additional
chemotherapy treatment and had
a stem cell transplant on July
25, 2000. After her transplant
Santana received radiation and
was cleared in April of 2001.

Mercy Hospital on Jan 10, 2000 and
started chemotherapy a couple
days later. After six rounds of
chemotherapy Santana’s tumor
had decreased in size by 50
percent, and on April 24, 2000
she had surgery to remove the
remainder of it.

Today Santana is a healthy 8-yearold who is full of energy. The only
noticeable effects of her treatment are
the hearing aids she wears and a scar
from her surgery. Santana doesn’t let
her fight with cancer hold her back,
and the compassion she shows to her
horses is a reflection of her love for life
and others.

Ride on Santana!

neuroblastoma
Introduction
	Neuroblastoma (neuro indicates nerves,
blastoma refers to a cancer that affects
immature or developing cells) is a tumor
of cells of neural crest origin that form the
adrenal medulla and sympathetic ganglia.
Tumors can appear anywhere along this
chain from the base of the neck to the
tailbone. It is the second most common
solid tumor in childhood after brain tumors
and accounts for approximately 8 percent
of all childhood cancers. Each year about
600 children in the United States will
develop neuroblastoma. The cause, like
most childhood cancers is unknown. This is
truly a disease of childhood as greater than
50 percent present before two years of age
and it is extremely rare in adolescents and
young adults. Neuroblastoma accounts for
50 percent of all tumors in infants less than
one year of age. Not all autonomic nervous
system tumors are malignant. There is a
benign tumor called ganglioneuroma and
a mixed tumor composed of benign and
malignant cells called ganglioneuroblastoma.
There is also a very unique form of malignant
neuroblastoma, called Stage 4S (see Page
19), that is known to spontaneously regress
without any therapy.

Clinical Presentation
Most neuroblastomas (about 2/3)
start in the abdomen with about 1/3 in the
adrenal glands (located above the kidneys).

The rest arise primarily in the chest and
neck. Metastatic spread typically involves
the lymph nodes, liver, bone, bone marrow,
and skin. Symptoms are typically a result of
either tumor invasion or of para-neoplastic
syndromes. First symptoms are often
vague and may include fatigue and loss
of appetite. A tumor in the abdomen may
cause a swollen stomach and constipation.
By contrast, infants with extensive disease
are often pale and cachectic, presenting
with fever, anorexia, irritability, and anemia
(resulting from spread to bone marrow and
bone). A tumor in the chest may cause
breathing problems and suggest pneumonia
as a result of bronchial obstruction. Tumors
pressing on the spinal cord may cause
weakness and an unstable gait, limp, or
even paresis (weakness) along with bladder
and/or anal sphincter dysfunction.
It is one of the few cancers in children
that release hormones (catecholamines)
that can cause changes in the body such
as constant diarrhea. Other paraneoplastic
syndromes can cause changes in some
functions of the brain causing opsoclonus
(rotary movements of the eyes) and
myoclonus (spastic jerks of the muscles),
both thought to be a result of antibody
formation. Besides “Dancing Eyes”, one
may see a Horner’s syndrome (sinking in of
the eyeball, ptosis of the upper eyelid, slight
elevation of the lower lid, constriction of the
pupil, narrowing of the palpebral fissure and
anhidrosis (a result of nerve compression of
the upper chest or neck). As well “Raccoon
Eyes” (periorbital edema and ecchymosis

with proptosis) is a classic finding, the result
of tumor invasion into the bones of the
orbits and sinuses. Skeletal involvement can
present as a hard lump, pain, or refusal to
bear weight. Skin involvement can present
with hemorrhagic skin nodules (Blueberry
Muffin lesions). Excessive sweating is
often seen related to excessive secretion of
catecholamines.

Work Up
In addition to a detailed history and
physical exam a variety of laboratory and
radiological exams are performed along
with pathological studies on tissue(s)
obtained. These tests allow us to properly
stage the degree of spread of the tumor as
well as provide important markers, which
are essential for treatment and prognostic
reasons, as well as to monitor the affects of
therapy.

Laboratory Studies
One of the characteristics of
Neuroblastoma is excessive production
of catecholamines: Vanillylmadelic Acid
(VMA), and Homovanillic Acid (HVA).
Elevation of one or both of these can often
be detected in a random (spot) sample
of urine. Ferritin, LDH, and Neuronspecific enolase can also be found to be
elevated in some neuroblastomas and can
be measured from a blood sample. Anemia
and thrombocytopenia are common findings
due to marrow invasion.
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Imaging Studies

Tissue Examination

Ultra Sound uses sound waves whose
echoes produce a picture. This is a relatively
quick, non-invasive procedure that is
often first obtained when concern arises
about the possibility of the presence of a
neuroblastoma, especially in the abdomen.
Once a mass is felt to be present, other
imaging studies are routinely done.
Computerized Axial Tomography
(CAT) scan of the neck, chest, abdomen and
pelvis is important to evaluate for metastatic
disease as well as to better visualize the
primary tumor. Evaluation of the head is also
often done to better visualize boney invasion.
	A Total Body Bone Scan involves an
intravenous injection of a radioactive tracer
(technetium 99). If the tumor has spread
to the bones this dye travels to, and shows
increased uptake in, areas of tumor spread.
	A Meta-Iodobenzylguanidine (MIBG)
scan also involves an intravenous injection.
MIBG attaches to neuroblastoma cells and
can indicate involvement of both organs
as well as bones. Not all tumors take up
MIBG, but in those that do this becomes an
additional tool to monitor tumor response to
treatment. In some instances (usually with
resistant or recurrent disease), therapy takes
advantage of MIBG sensitive tumors.

	A Bone Marrow Aspirate and Biopsy
are performed from both the left and right
posterior iliac crests (the back of the pelvis)
to determine whether or not the tumor has
spread to this organ. This procedure can be
done with local anesthetic agents such as
lidocaine and/or a numbing cream along with
moderate sedation (Midazolam and Fentanyl)
or deep sedation (propofol). This is done in
the hospital floor or clinic procedure room
along with a representative from Child Life
and the option of the presence of family
members. When necessary, this procedure
is done in the Operating Suite with the child
completely asleep using
general anesthesia.
This may coincide when
the surgeon is removing
or biopsying the primary
tumor and/or providing
intravenous access
with the placement of a
central line.
Surgery is required
for both diagnostic and
therapeutic reasons. If
possible, it is preferable
to remove all or as
much of the primary
tumor as possible. If
this can’t be done
(especially at the
risk of damaging vital
organs or vessels)
a biopsy to obtain

tissue is performed. In addition, in order to
facilitate the delivery of chemotherapy in a
safe and easy fashion as well as providing a
means of monitoring therapy, the surgeons
will place a central venous line (often at
the same time, thus limiting the child to
only one anesthetic interaction). Because
of the need for two lumens and the small
body size as well as the possibility of bone
marrow transplantation, this is usually an
externalized catheter, but indwelling ports are
sometimes used.

Staging
Staging is based upon the spread
of tumor and the surgical resection
at diagnosis. Today, the International
Neuroblastoma Staging System is used
(INSS) which is outlined as follows:
Stage 1: Localized tumor that is completely
surgically removed at diagnosis.
Stage 2A: Localized tumor that cannot be
completely surgically removed at diagnosis.
It is on one side of the body. Lymph nodes
on the same side of the tumor may have
tumor cells present. Lymph nodes outside of
the tumor are free of cancer.
Stage 2B: Localized tumor that may or may
not be able to be totally removed by surgery.
It is on one side of the body. Nearby
lymph nodes outside the tumor contain
neuroblastoma cells, but the cancer has not
spread to lymph nodes on the other side of
the body or elsewhere.
Stage 3: Large tumor that has spread
across the middle of the body that cannot be
surgically removed at diagnosis.
Stage 4: Tumor of any size that has
metastasized (spread) to distant lymph
nodes, bone marrow, bone or liver.
Stage 4S: Special stage that applies only
to a child less than one year old. Small,
localized tumor that has metastasized
(spread) to liver, skin, and/or bone marrow,
and specifically does not spread to the bone.
	Neuroblastoma that presents as
Stage 4S is a unique tumor that is known
to spontaneously regress during the first
year of life without therapy. Occasionally
short periods of therapy are required to
minimize local damage until the time that
spontaneous regression begins. Despite its
identical microscopic appearance to other

Children’s Mercy Neuroblastoma
Gender and Stage Distribution
10 Year Comparison
YEAR

TOTAL

MALE

2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
TOTALS

7
13
11
7
9
4
6
5
2
8
72

2
7
7
3
4
0
4
3
0
3
33

FEMALE STAGE
1
5
2
6
3
4
0
4
1
5
1
4
0
2
1
2
2
2
0
5
1
39
11

types of neuroblastoma, this propensity to
spontaneously regress (even in the face of
its metastatic spread) requires its special
staging designation.

Prognostic Factors:
Besides the stage, there are four
features that have prognostic value and help
determine the appropriate therapy. These
are:
1) Age: Younger children (less than 18
months) are more likely to be cured than
older children.
2) Tumor histology: Originally described by
Dr. Shimada, the appearance of the tumor
cells under the microscope are determined
to be either “Favorable” or “Unfavorable”
histology depending on how active the cells
look. Tumors with unfavorable histology tend
to behave more aggressively.

STAGE
2
2
3
3
0
1
0
0
0
1
3
13

STAGE
3
0
2
3
0
1
0
2
0
0
0
8

STAGE
4
2
5
5
6
6
4
2
2
1
4
37

STAGE
4S
1
0
0
0
0
0
1
1
0
0
3

3) Tumor MYCN status: MYCN is
an oncogene that regulates tumor cell
growth. Tumor cells can have a single
copy or multiple copies of this gene
(called MYCN amplification). Tumors with
MYCN amplification tend to behave more
aggressively.
4) Tumor DNA index (also called
Ploidy): Describes the number of
chromosomes in the tumor cells, compared
to the number in normal cells. Cells
with about the same amount of DNA as
normal cells are classified as “Diploid”.
Neuroblastoma cells with increased amounts
of DNA are termed “Hyperdiploid”. In
infants, hyperdiploid cells tend to be
associated with earlier stages of disease,
respond better to chemotherapy, and usually
predict a more favorable prognosis than
diploid cells.
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Risk Groups
Based on the stage along with the
prognostic factors listed above, a patient is
placed into one of three risk groups: Low,
Intermediate, and High. Based on past
studies, 12 months of age is used as an
important cut off point, but based on review
of the most recent results, it appears that in
future studies this cutoff point will extend to
become 18 months.
Low Risk:
n All Stage 1
n Stage 2A or 2B who are < 12 months
old
n Stage 2A or 2B who are > 12 months
old and have a single copy of the MYCN
gene
n Stage 2A or 2B who are > 12 months
old who have extra copies of MYCN gene
but have favorable histology
n Any Stage 4S who have a single copy of
MYCN, favorable histology
and hyperdiploid
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Intermediate Risk:
n Stage 3 who are < 12 months old and
have a single copy of the MYCN gene
n Stage 3 who are > 12 months old and
have a single copy of the MYCN and
favorable histology
n Stage 4 who are < 12 months old and
have a single copy of the MYCN gene
n Stage 4S who are < 12 months old and
have a single copy of the MYCN gene,
and either normal DNA Ploidy or has
unfavorable histology

High Risk:
n Stage 2A or 2B who are > 12 months
old and have extra copies of the MYCN
gene and unfavorable histology
n Stage 3 who are < 12 months old and
have extra copies of the MYCN gene
n Stage 3 who are > 12 months old and
have a single copy of the MYCN gene
and has Unfavorable histology
n Stage 3 who are > 12 months old and
have extra copies of the MYCN gene
n Stage 4 who are < 12 Months old and
have extra copies of the MYCN gene
n Stage 4 who are > 12 months old
n Stage 4S who are < 12 months old and
have extra copies of the MYCN gene

Risk Adjusted Treatment
Therapy is adjusted according to one of
three risk categories. This risk reflects the
risk of the neuroblastoma recurring.
Low Risk patients are treated with
surgical resection and supportive care.
If the tumor recurs or progresses than once
again the treatment of choice would be
surgery and supportive care. If the tumor
is not resectable, than chemotherapy
agents are used. Patients will receive
four (4) cycles (a group of chemotherapy
agents given together over a short period
of time) of chemotherapy given every three
weeks. Those who recur or progress with

Intermediate Risk disease receive four (4)
cycles if they have favorable histology or
eight (8) cycles if they have unfavorable
histology.
Intermediate Risk patients are
treated with a combination of surgery and
chemotherapy. Patients first undergo
surgery to remove as much of the primary
tumor and involved lymph nodes as can
be safely accomplished with the minimum
morbidity. Patients then receive four
(4) cycles of chemotherapy if they have
favorable histology and eight (8) cycles
of chemotherapy if they have unfavorable
histology. If the tumor had not been
removed previously, then surgical removal of
residual tumor is done at the completion of
chemotherapy.
Radiation therapy is not routinely given
to intermediate risk patients. It is used to
treat in the following situations:
n Progressive clinical deterioration despite
chemotherapy and/or surgery
n Partial Response (50-90 percent
Reduction) after eight (8) cycles
of chemotherapy in patients with
unfavorable histology
n Partial Response following surgery
for local recurrence more than three
months after completing protocol
therapy
High Risk patients are treated with
a combination of therapies. As will be
discussed, the prognosis for these patients
is considerably less favorable than those in
the Low or Intermediate Risk groups. As

with the other patients, surgery is usually the
first step in treatment. Again, the goal is to
remove as much of the tumor as possible
without causing significant morbidity. If there
is metastatic disease present, usually no
attempt is made to approach this surgically.
Chemotherapy is then employed.
Patients receive two (2) cycles of
chemotherapy and then have their own
Peripheral Blood Stem Cells (PBSC)
collected and stored for later in their therapy.
Following this, the patients receive three
(3) more cycles of chemotherapy and then
have their definitive surgery to remove any
residual tumor (if any exists). There is then
one (1) additional cycle of chemotherapy,
which is then followed by the Bone Marrow
Transplant (BMT) portion of the treatment.
At this point the patient receives additional
high dose chemotherapy, which is different
from what the patient has seen previously.
An important side effect from this therapy

is that it causes the
patient’s bone marrow to
be ablated (destroyed),
thus requiring the
immediate subsequent
infusion of the patient’s
PBSC’s collected earlier
to ensure recovery.
Following recovery
from this process patients
undergo radiation therapy
to the primary tumor
bed, and any metastatic
areas of disease that were
shown to be involved with
tumor just prior to the
transplant process.
Patients then proceed to a phase where
they take an oral biologic agent, 13-cisretinoic acid (accutane). Neuroblastoma
cells have shown that when they are
exposed to this agent, they exhibit decreased
proliferation, decreased expression of MYCN,
and morphologic differentiation.
Other therapies that have been used
to treat these patients include the use of
agents bound to MIBG and other antibodies
specific to a patient’s tumor. MIBG
associated therapies remain limited to very
few institutions. Antibody therapy is under
investigation at all participating Children’s
Oncology Group (COG) centers including
Children’s Mercy.
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Treatment Related
Side Effects

n

Vincristine can cause a decrease
in reflexes and inhibit proprioception
(the sensory nerve endings that give
information concerning movements and
position of the body) causing messier
drawing and handwriting and increased
clumsiness (especially when running).
More problematic is the constipation
that is caused in a population where this
is already often a significant problem.

n

Cyclophosphamide may produce
bladder inflammation and blood in
the urine (hemorrhagic cystitis) and/or
damage to the kidneys with subsequent
loss of salt and minerals in the urine. It
is not uncommon for patients to need
supplementation of these nutrients
during and after therapy is concluded.

n

Cisplatin may also cause some kidney
damage as well as hearing loss or
deafness. It is not unusual for children
to require hearing aids during or after
therapy is completed.

n

Doxorubicin may cause heart damage
and can cause a chemical burn to the
skin if it leaks out and comes in contact.

The following medications are the
backbone of chemotherapy:
n
	Cyclophosphamide
n Doxorubicin
n Vincristine
n
	Cisplatin
n
	Etoposide
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While effective in treating neuroblastoma
these medications also can have significant
side effects that affect the patient in both
the short and long run.
	Nausea and vomiting, hair loss,
depression of the immune system, and
suppression of the bone marrow are
common. Infection can be life threatening
and often there are hospitalizations inbetween cycles of chemotherapy to treat
presumed and true infections. Appetite can
be suppressed to the point that weight loss
requires supplementation either through
their implanted central line as Total Parental
Nutrition (TPN), or enterally through a
Naso-Gastric (NG) tube which is a flexible
tube placed through the nasal cavity down
into the gastro-intestinal (GI) tract or having
a “button” or gastrostomy tube (G-tube)
surgically placed with a valve providing direct
access to the GI tract via the stomach.
In addition, each chemotherapy agent
may have some unique side effects due to
the drug itself or from a break down product
that occurs as the body metabolizes it.

Treatment Outcome
There is a considerable difference in
outcome for the Low and Intermediate Risk
patients compared to the High Risk patients.
Patients with Low Risk disease have shown
long term survival rates of greater than 90

percent while Intermediate Risk patients
have shown long term survival rates close to
the same 90 percent.
This outcome however is not what
has been shown in the High Risk patients.
On the positive side, there has been
considerable improvement over the many
years of treating these patients. From 1978
through 1985 long-term survival for this
group was only about 10 percent. This rose
to about 25 percent from 1986-1995. With
current treatments, we have again seen
improvement, but still less than desirable at
only around 40-45 percent.
Through clinical studies, we have
learned that those children treated with
13-cis-retinoic acid do better than those
that did not receive this as part of their
therapy. In addition we learned that children
that underwent autologous bone marrow
transplantation did better than those that
only were treated with chemotherapy alone.
We also learned that screening for
neuroblastoma at an earlier age and
hopefully at an earlier stage resulting in
an improved outcome did not pan out as
was hoped. While the number of children
diagnosed with neuroblastoma increased,
the rate for High Risk children did not
decrease as hoped. What did occur was
that many children who previously would
have gone undetected (due to spontaneous
regression and without any consequence)
were now being identified in the newborn
period. Meanwhile, many parents underwent
an increased incidence of anxiety and worry.
It seems that while there is much similar

between these tumors, those that cause
High Risk disease truly act in a different
manner.

Other Strategies and Future
Directions
	As we succeed with treatment, the
goal begins to switch towards decreasing
treatment morbidity both in the short term
and especially in the long term. While
reducing therapy intensity further is not that
practical in the Low or Intermediate Risk
groups one likely change in the next round
of therapies will be to change the prognostic
cutoff age from its current 12 months of age
to 18 months of age. When this was looked
at with the most recent data it appears
that several hundred children could be
treated successfully while exposing them to
significantly less therapy.
	As mentioned earlier, because
neuroblastoma cells tend to be radiation
sensitive, there have been several therapies
looking at attaching radionuclides to
MIBG, somatostatin analogs, or anti-GD2
antibodies. These treatments are still
investigational, are not readily available at
most institutions, and are not active in all
patients.
	Neuroblastomas are often heavily
vascularized tumors and the degree of
vascularity often correlates with biologic
features such as NMYC amplification.
Agents that work against the formation of
new blood vessels, antiangiogenic agents
are being looked at but have been slow to

come to clinical trials.
In the laboratory, inhibiting Tyrosine
Kinase activity has shown to inhibit the
growth of neuroblastoma cells. Others such
as the EGF receptor inhibitor gefitinib are
also being looked at.
In addition, other strategies like looking
at ways to prevent drug resistance are in
investigation.
For now, the most likely changes will be

to explore newer agents most likely coming
from experience in treating relapsed and
resistant disease that has shown to be
effective and moving them into frontline
therapies. Ongoing participation in clinical
trials will be essential to bring the most
current therapies available to these patients
as well as allowing us to continue to make
much needed progress in treating this
disease.
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satala

Here at Children’s Mercy we know
that the children we serve today will
be the leaders of tomorrow. That was
no exception in the case of 3-year-old
Satala.

neuroblastoma. Young Satala
started his eight month treatment on
chemotherapy right away, and later
received a bone marrow transplant on
August 17, 2006.

In 2006 Satala’s mother took him
to see the family doctor because he
had been complaining about his legs
hurting for three or four months.
Originally the doctor supported the
mother’s suspicion they were just
growing pains, but took an x-ray just to
be sure.

After his bone marrow transplant
Satala was cancer free, but continued
coming to Children’s Mercy two or
three weeks a month to participate in
an antibodies study to ensure that he
remained healthy.
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After looking at Satala’s x-ray, his
doctor immediately referred him
to Children’s Mercy where he was
diagnosed, on Jan. 27, 2006, with

Today Satala is almost 5 years old. His
mother refers to him as “an old soul,”
and the doctors at Children’s Mercy can
be proud in knowing that they saved the
live of a very intelligent young child.

Satala loves computers and is
developed way beyond his years. He
currently speaks both English and
Spanish, and is learning Chinese from
his aunt. Satala is definitely a child
with a bright future and we hope to see
great things from him.

Buena Suerte Satala!

diagnostic and treatment 						
support services
Surgery

Cytogenetics

The pediatric surgeon is often
involved in the diagnosis and treatment of
neuroblastoma, as well as operative staging
of the disease. More than half of NB arise in
the abdominal cavity. Tumor size, location,
degree of vascular and visceral involvement
is assessed, and resectability determined.
Although generally it is true that complete
resection offers the best hope for a long
term cure, biologically more favorable
tumors are more likely to be amenable to
complete resection. Sacrifice of major organ
/ vessels at attempted initial resection is
not necessary. Minimally invasive surgery
play only a minor role in the treatment
of NB. Some centers have performed
laparoscopic biopsy as an initial approach for
unresectable disease.
	A second look operation after adjuvant
therapy is preferable to life-threatening
resection initially. Operative therapy for
neuroblastoma is therefore stage-based:
INSS (International Neuroblastoma Staging
System) Stage 1 and early Stage 2 tumors
should be completely resected, with an
expected survival in the 85 - 90 percent
range. Advanced stage tumors undergo
chemo and or radiation therapy after the
diagnosis is confirmed, with delayed primary
or second-look operation. Post-operative
complications occur in about 10 percent
of patients, dependent on the stage of the
disease.

	Neuroblastoma (NB), the most common
extracranial solid tumor in children, is derived
from primitive neural crest cells. NBs
arise in the adrenal gland, the sympathetic
nerve ganglia, and other sites. Cytogenetic
anomalies distinguish prognostic groups
in neuroblastoma (NB). Chromosome
aberrations that correlate with a poor
outcome are deletion of the chromosome
1 short arm, gain of copies of chromosome
17 long arm, MYCN gene amplification,
and a diploid or near-diploid karyotype.
These aberrations are closely associated
with advanced stage disease. However,
1p deletions in stage I, II, and IVS tumors
identify patients with high-risk disease in
the absence of MYCN gene amplification.
A hyperdiploid or near-triploid karyotype
without the aforementioned anomalies
is prognostically favorable. MYCN gene
amplification manifests as double minute
chromosomes (dmin) or homogeneously
stained regions (hsr) at the cytogenetic level.
Fluorescence in situ hybridization (FISH)
analysis using touch preparations of tumor
material or cytogenetically harvested cells
provides a quick assessment of MYCN gene
status.

The karyotype:
45,XX,der(1;17)(q10;q10),der(2)add(p16)del(q11.2q24.2)inv
(q11.2p16),-10,+17,dmin
Shows an unbalanced translocation between chromosomes 1
and 17 that result in loss of 1p and gain of 17q
Shows an unbalanced rearrangement of chromosome 2 that
results in loss of portions of chromosome 2 short and long arms
Shows loss of one copy of chromosome 10
Shows two normal copies of chromosome 17 in addition to the
chromosome 17q translocated to chromosome 1; the result is
3 copies of 17q
Shows gain of innumerable double minute chromosomes

•
•
•
•
•

•
• Shows the double minute chromosomes as small dots

The metaphase cell from which the karyotype was made:

surrounding the chromosomes
The FISH of interphase nuclei:
Shows the double minute chromosomes hybridized with the
MYCN gene probe (green); two red signals show the normal copy
number of chromosome 2; nucleus with two red and two green
signals is a normal cell

•
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Pathology
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	Children’s Mercy Hospital provides
a multidisciplinary team approach to the
diagnosis and treatment of Neuroblastoma
(NB). This team includes a pediatric
pathologist that confirm or establish the
diagnosis of NB , and cytogeneticist who
evaluates the chromosomes and certain
genes in the tumor. The pathologist’s
primary function is to distinguish NB from
other malignant tumors that share a socalled “small round cell” microscopic
appearence common to many childhood
malignancies including leukemia,
lymphomas, and several childhood
sarcomas. A variety of monoclonal
antibodies are now utilized to assist in
making a reliable distinction. In addition,
tumor samples are submitted for a variety of
ancillary studies including determining tumor
histologic grade, DNA content (Ploidy), and
the number of copies of the N-Myc gene
that bear on the prognosis of the patient and
alter treatment accordingly.
The Pathology Laboratory processes
thousands of specimens each year in the
diagnosis of new and recurrent tumors.
The department performs a variety of tests
directly used in the diagnosis and followup care of cancer patients. Children’s
Mercy Laboratory department is staffed 24
hours each day, seven days a week and is
licensed by the federal government (CLIA)
and accredited by the College of American
Pathologists (CAP), the Joint Commission
on the Accreditation of Health Care

Organizations (JCAHO), as well as state and
federal agencies.

Radiology
The mission of the Department of
Radiology is to provide state-of-the-art
medical imaging services in a safe and
caring environment to patients, families, and
referring physicians. Services are tailored
to meet the patient’s medical needs while
treating each child as a unique individual.
The Department of Radiology provides
computerized tomography (CT) including
the latest development in multi-detector
CT, Magnetic Resonance Imaging (MRI),
ultrasound, nuclear medicine, conventional
and fluoroscopic studies, as well as, leading
edge interventional radiology procedures.
The department is staffed by fellowship
trained, board certified pediatric radiologists
and a dedicated group of technologists,
nurses, and clerical staff. Our mission
statement is taken very seriously and guides
our daily practice.
One of the key medical imaging studies
in the staging and follow-up evaluation of
patients diagnosed with neuroblastoma
is the Nuclear Medicine MIBG scan with
SPECT. SPECT stands for Single Photon
Emission Computed Tomography, and
allows for thin section tomograms to be
taken in multiple planes. This enables
detection of small lesions with a high
target to background ratio. MIBG also
helps in distinguishing viable tumor tissue

from residual fibrosis which is a valuable
prognostic indicator in patients who are
undergoing or are post treatment.

Radiation Therapy
	Radiation therapy was used following
surgery to treat residual neuroblastoma
in the 1950s. The use of chemotherapy
changed the management of the disease
since that time, and the techniques, doses
and volumes of radiation therapy have
continued to evolve with time. Often, the
patients that receive radiation have had a
stem cell transplant. That is an important
consideration in determining the regions
that will be treated as well as the doses
that will be delivered. As our imaging
studies become more sophisticated, we
have modified the areas that are treated
in patients. The daily doses and total
doses are also being evaluated, with an
emphasis on customized and tailored
treatments for patients, depending on
their response to treatment. The Kansas
City Cancer Center has partnered with the
Division of Hematology/Oncology to ensure
each pediatric patient diagnosed with
neuroblastoma is offered the most effective
treatment option available.
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